CATALYST BIOSCIENCES, INC. STOCK OPTION AGREEMENT — EARLY EXERCISEOption Agreement • May 22nd, 2015 • Targacept Inc • Pharmaceutical preparations • California
Unless otherwise defined herein, the terms defined in Schedule A, attached hereto and incorporated herein by reference, shall have the same defined meanings in this Stock Option Agreement.
CATALYST BIOSCIENCES, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • May 22nd, 2015 • Targacept Inc • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of this 14th day of January 2015, by and between Catalyst Biosciences, Inc., a Delaware corporation (the “Company”), and Fletcher Payne (“Indemnitee”).
LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • May 22nd, 2015 • Targacept Inc • Pharmaceutical preparations • California
This LICENSE AND COLLABORATION AGREEMENT (the “Agreement”) is entered into as of September 16, 2013 (the “Effective Date”) by and between Catalyst Biosciences, Inc., a Delaware corporation having a principal place of business at 260 Littlefield Avenue, South San Francisco, CA 94080 (“Catalyst”), and ISU Abxis, a Korean corporation having a principal place of business at Pangyo Global R&D Center, C Bldg, 5th Floor, 696-1 Sampyoung-dong, Bundang-gu, Sungnam, 463-400, Korea (“ISU”). ISU and Catalyst may each be referred to as a “Party” or collectively be referred to as the “Parties”.
CATALYST BIOSCIENCES, INC. CONSULTING AGREEMENTConsulting Agreement • May 22nd, 2015 • Targacept Inc • Pharmaceutical preparations • California
This Consulting Agreement (this “Agreement”) is entered into as of January 14, 2015 (the “Effective Date”) between Catalyst Biosciences, Inc., a Delaware corporation (“Company”), and Fletcher Payne (“Consultant”).
AMENDMENT NO. 1 TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • May 22nd, 2015 • Targacept Inc • Pharmaceutical preparations
This AMENDMENT NO. 1 TO LICENSE AND COLLABORATION AGREEMENT (the “Amendment”) is entered into as of October 31, 2014 (the “Effective Date”) by and between Catalyst Biosciences, Inc., a Delaware corporation having a principal place of business at 260 Littlefield Avenue, South San Francisco, CA 94080 (“Catalyst”), and ISU Abxis, a Korean corporation having a principal place of business at Pangyo Global R&D Center, C Bldg, 5th Floor, 696-1 Sampyoung-dong, Bundang-gu, Sungnam, 463-400, Korea (“ISU”). ISU and Catalyst may each be referred to as a “Party” or collectively be referred to as the “Parties”.
Nassim Usman, Ph.D. Chief Executive OfficerTargacept Inc • May 22nd, 2015 • Pharmaceutical preparations
In recognition of Catalyst Biosciences, Inc.’s desire to retain your services as an employee, I am pleased to amend that certain letter agreement dated 15 February 2007 (the “Agreement”). Section II of the Agreement is hereby amended and restated in its entirety as follows:
Nassim Usman, Ph.D. Chief Executive OfficerTargacept Inc • May 22nd, 2015 • Pharmaceutical preparations
In recognition of Catalyst Biosciences, Inc.’s desire to retain your services as an employee, I am pleased to amend that certain letter agreement dated 15 February 2007 (the “Agreement”), as amended 24 September 2008. Section II of the Agreement is hereby amended and restated in its entirety as follows:
